Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventana develops test for Novartis' Gleevec:

This article was originally published in Clinica

Executive Summary

Ventana Medical Systems is developing a diagnostic kit designed for use with Novartis Pharmaceutical's drug Gleevec (imatinib), the first signal transduction inhibitor approved in the US. The FDA approved Gleevec in 2001 for use with chronic myeloid leukaemia patients and subsequently extended its labelling in February 2002 for treating patients with c-kit positive inoperable and/or metastatic malignant gastrointestinal stromal tumours. Ventana, of Tucson, Arizona, is collaborating with Novartis to develop a diagnostic kit for c-kit and to file a premarketing approval (PMA) application with the FDA for the test.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT066576

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel